Emergent BioSolutions Inc.

NYSE:EBS

Biotechnology

Healthcare
$5.50 -2.58%

-$0.21 today

Market cap
$282.78M
Beta
2.33
P/E (TTM)
-47.9
EPS (TTM)
-$0.17
52W Low $5.62High $14.06

Volume 0.82M

Average 0.78M

EBS Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Emergent BioSolutions Inc.NYSE: EBS

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables dips below year-ago levels

Q1 FY2026 accounts receivables of $38.9M (cash outflow) fell 46.9% year over year, behind the +225.6% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at -40.0% a year.

Context

  • Accounts receivables amounted to 3.4% of revenue in FY2025, up 1.1 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -46.9% toward the trailing-twelve-month pace of +225.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$38.9M-175.0% QoQ
Last fiscal yearDec 2025
$25.5M+204.5% YoY
LTMMar 2026
$59.9M+225.6% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-46.9%——
1 year+204.5%——
3-year CAGR-40.0%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
25.5M USD
Year-over-year change
+204.5%

Accounts Receivables vs competitors

How EBS compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +225.6% is the 2nd highest of 7, against a peer median of +72.7%.
  • Accounts receivables amounts to 8.9% of revenue for EBS, versus a peer median of 2.9%.
EBS Competitors
Accounts Receivables for EBS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EBSEmergent BioSolutions Inc.LTM Mar 2026$59.9M USD+225.6%-40.0%8.9%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$51.06M USD+91.4%+77.2%12.2%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$16.97M USD+54.1%+136.4%3.3%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$8.4M USD-40.2%-25.8%2.8%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$3.65M USD+482.9%—7.3%
SIGASIGA Technologies, Inc.LTM Mar 2026$2.68M USD-75.5%-22.4%2.9%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$36K USD+167.9%——
CMPSCOMPASS Pathways plcLTM Mar 2026$0 USD———
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
PRTAProthena Corporation plcLTM Mar 2026$0 USD——0.0%
SNDLSNDL Inc.LTM Mar 2026CA$0 CAD——0.0%
Peer median (excluding EBS) —+72.7%+27.4%2.9%

Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income230.9M(211.6M)(760.5M)(190.6M)52.6M
Depreciation & Amortization123.8M143.3M125.1M108.8M95.8M
Deferred Income Tax46.9M(28.6M)(8.9M)(5.5M)(4M)
Stock-Based Compensation42.4M45.1M23.1M18M16.2M
Change in Working Capital(156.4M)(2.1M)(70.3M)88.7M(22.4M)
Accounts Receivables(48.2M)118.1M(21.6M)(24.4M)25.5M
Inventory(44M)(57.1M)600K(24.5M)(30.3M)
Accounts Payables(2.5M)(14M)10.6M(33M)(8.4M)
Other Working Capital(61.7M)(49.1M)(59.9M)170.6M(9.2M)
Other Non-Cash Items33.5M19.8M485.2M39.3M32.4M
Operating Cash Flow321.1M(34.1M)(206.3M)58.7M170.6M
Capital Expenditures(225M)(115.8M)(51.6M)(22.9M)(13.8M)
Acquisitions (Net)00270.2M00
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0(265.5M)(6.3M)148.1M83.2M
Investing Cash Flow(225M)(381.3M)212.3M125.2M69.4M
Debt Repayment(35.9M)564.2M(543.4M)(198.4M)(112.5M)
Common Stock Issued008.4M9.3M2.2M
Common Stock Repurchased(106M)(82.1M)00(24.9M)
Dividends Paid00000
Other Financing Activities900K(900K)(700K)(900K)(1.4M)
Financing Cash Flow(141M)481.2M(535.7M)(190M)(136.6M)
Effect of Forex Changes(300K)500K(1.2M)0100K
Net Change in Cash(45.2M)66.3M(530.9M)(6.1M)103.5M
Free Cash Flow96.1M(149.9M)(257.9M)35.8M156.8M

Emergent BioSolutions Inc.

NYSE:EBS

Intrinsic Alpha fair value

Locked

Current Price

$5.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.